TRCT
DRMA icon

Tower Research Capital (TRC)’s Dermata Therapeutics DRMA Stock Holding History

Tower Research Capital (TRC)’s Portfolio DRMA Stock Details DRMA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.98K Buy
3,860
+3,144
+439% +$3.96K ﹤0.01% 4322
2026
Q1 		$866 Sell
716
-1,283
-64% -$2.16K ﹤0.01% 4763
2025
Q4 		$4.64K Buy
1,999
+1,573
+369% +$5.14K ﹤0.01% 4195
2025
Q3 		$2.14K Sell
426
-106
-20% -$644 ﹤0.01% 4677
2025
Q2 		$3.11K Buy
532
+352
+196% +$2.7K ﹤0.01% 4548
2025
Q1 		$1.94K Buy
180
+41
+29% +$504 ﹤0.01% 4624
2024
Q4 		$1.88K Sell
139
-150
-52% -$1.94K ﹤0.01% 4942
2024
Q3 		$4.74K Buy
289
+116
+67% +$2.31K ﹤0.01% 4434
2024
Q2 		$4.14K Buy
173
+135
+355% +$5.87K ﹤0.01% 4813
2024
Q1 		$2.36K Sell
38
-5
-12% -$344 ﹤0.01% 5061
2023
Q4 		$3.92K Buy
43
+9
+26% +$975 ﹤0.01% 5028
2023
Q3 		$5.45K Sell
34
-4
-11% -$767 ﹤0.01% 4718
2023
Q2 		$9.38K Sell
38
-1
-3% -$273 ﹤0.01% 4296
2023
Q1 		$7K Buy
39
+37
+1,850% +$21.6K ﹤0.01% 4731
2022
Q4 		$2K Hold
2
– – ﹤0.01% 5349
2022
Q3 		$2K Hold
2
– – ﹤0.01% 5545
2022
Q2 		$3K Buy
2
+1
+100% +$2.06K ﹤0.01% 5362
2022
Q1 		$3K Hold
1
– – ﹤0.01% 5357
2021
Q4 		$3K Sell
1
-1
-50% -$8.84K ﹤0.01% 5431
2021
Q3 		$21K Buy
+2
New +$23.7K ﹤0.01% 3661

Other funds holding DRMA

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $8.23B AUM 17.62% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return
AA
Advisory Alpha Holland, Michigan $4.08B AUM 20.62% 1-Year Est. Return
MA
MCF Advisors Covington, Kentucky $2.8B AUM 19.11% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
SS
SBI Securities Tokyo, Japan $4.4B AUM 74.26% 1-Year Est. Return

Tower Research Capital (TRC)'s DRMA Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Dermata Therapeutics (DRMA) stake by 439% in Q2 2026, buying an estimated $3.96K and bringing the position to 3,860 shares worth $4.98K. The position accounts for ﹤0.01% of the portfolio, ranked #4322.

Tower Research Capital (TRC) first reported a position in DRMA in Q3 2021 and has held it in 20 quarters since. The position peaked at $21K in Q3 2021. 13 funds tracked by Wall St. Rank hold DRMA as of Q2 2026.

  • Tower Research Capital (TRC) held 3,860 shares of Dermata Therapeutics worth $4.98K as of Q2 2026.
  • Tower Research Capital (TRC) bought 3,144 Dermata Therapeutics shares in Q2 2026, an estimated $3.96K.
  • Dermata Therapeutics made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #4322 holding.
  • Tower Research Capital (TRC) first reported a position in Dermata Therapeutics in Q3 2021 and has held it in 20 quarters since.
  • Tower Research Capital (TRC)'s Dermata Therapeutics position peaked at $21K in Q3 2021.
  • 13 funds tracked by Wall St. Rank held Dermata Therapeutics as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.